Lyell Immunopharma
Elizabeth (Beth) Saccone, M.B.A., ASQ LSSBB has a diverse work experience spanning various industries and roles.
Elizabeth (Beth) is currently working at Lyell Immunopharma as the Senior Director of Business Operations & Program Management, a position they have held since April 2022. Prior to this, they were the Director of Operations and Program Management at Lyell Immunopharma from September 2020 to April 2022.
Before joining Lyell Immunopharma, Elizabeth worked at AstraZeneca in multiple roles. Elizabeth (Beth) served as the Director of Business Continuity Planning & Risk Management, Global Supply Chain from September 2019 to September 2020. Prior to that, they held roles as Associate Director of Global Biologics Operations Business Improvement & Capability, Senior Manager of Global Biologics Supply Chain Center of Excellence, and Senior Manager of Manufacturing Excellence, contributing to enhancing operational efficiency and effectiveness.
Elizabeth also gained valuable experience at DaVita Healthcare Partners as the Corporate Senior Manager of Operations Strategy & Innovation from March 2015 to March 2016. Elizabeth (Beth) also worked at Amgen as the Site Operational Excellence and Learning & Performance Lead from July 2013 to December 2014, and at Genentech as the Operational Excellence Manager, Quality Training Business Partner, and Training Program Manager from 2005 to 2013, leading improvement initiatives and training programs.
Earlier in their career, Elizabeth worked in Intellectual Property Research at Technology and Patent Research Intl., Inc. from 2004 to 2005, conducted Epidemiology Research at TUFTS UNIV. SCHOOL OF MEDICINE from 2002 to 2003, and conducted Type 2 Diabetes Research at Harvard Medical School from 2001 to 2002.
Elizabeth Saccone's extensive work experience demonstrates their expertise in operations, program management, risk management, and operational excellence across multiple industries. Elizabeth (Beth) has a proven track record of driving improvement initiatives and implementing effective strategies to optimize business performance.
Elizabeth Saccone, M.B.A., ASQ LSSBB, pursued their education in a chronological order. Elizabeth (Beth) first attended College of Charleston from 1995 to 1999, where they earned their Bachelor of Science degree in Psychology. Following this, they enrolled at Tufts University, completing their studies in Biology/Chemistry in 2003. Elizabeth later decided to further their education by attending Regis University from 2015 to 2017. Here, they obtained their Master of Business Administration (M.B.A.) degree with a focus on Operations Management. Additionally, Elizabeth obtained their Lean Six Sigma Black Belt certification from ASQ in March 2010.
This person is not in any offices
Lyell Immunopharma
Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs).